-
Swallowed by silt: Survivors recount Nepal flood horror
-
Delays in Cancer Radiotherapy and Surgery Target Times
-
Germany's Merz hosts 'frugal' leaders ahead of EU budget battle
-
Acrid stench, charred walls reveal devastation of Pakistan infant ward fire
-
Barca sign Croatia goalkeeper Livakovic
-
Norway holds its breath as King Harald's health deteriorates
-
Rain delays England's bid to put off-field incidents behind them
-
Germany reports record 15,800 heat-related deaths this summer
-
World record holder Sawe withdraws from Berlin Marathon
-
YouTuber Chris Sails Arrested for Allegedly Falsifying Emergency Report
-
Driven by faith, activists stand up to fellow Jews to protect Palestinians
-
Dinusha defiant as Sri Lanka lead by 170 in India Test
-
Therapy Culture Performance: How the Lindsay Clancy Trial Sparked a Trend of Viral Maternal Distress
-
Taiwan lawmakers approve $7.6 bn drone budget as China threat grows
-
Norway's King Harald, 89, in 'extremely serious' condition
-
TechCentral.ie Daily Briefing: Agentic AI Firm Doubles Headcount to 60
-
How a glacier collapse may have caused Nepal-Tibet disaster
-
KiiChain Integrates TRON to Expand 24/7 On-Chain FX and Stablecoin Payments
-
Harmovest Capital Strengthens Global Financial Services Through Technology and Compliance
-
Japan to survey animal cafes over hygiene, welfare concerns
-
Nvidia to buy AI platform Hugging Face for $12.9 bn: report
-
Desperate families search for missing after Nepal floods
-
Palace intrigue in Uganda as succession battle heats up
-
The missing in Nepal-Tibet flash floods
-
'Housing First' approach gets Swedish city's homeless off streets
-
Search for 1,300 missing after deadly Nepal-Tibet floods
-
Czech duo Muchova and Mensik win US Open mixed doubles title
-
Once a top export, prized Kashmir carpet fades
-
Japan's 'polka dot queen' artist Yayoi Kusama dies aged 97
-
Search for 1,000 missing after deadly Nepal-Tibet floods
-
Nepal-Tibet disaster: what we know
-
Park So-yeon first woman to play for eSports powerhouse South Korea
-
China deploys record number of ships around Taiwan as pressure grows
-
Yayoi Kusama: Japan's kaleidoscopic, troubled 'polka dot queen'
-
Ruthless Bayern target treble as rivals reboot on Bundesliga return
-
Euro champ Hunt 'on her toes' against world's best in Zurich 100m
-
What experts know so far about Nepal's deadly floods
-
Asian chip firms lifted by Nvidia forecast but broader markets struggle
-
UEFA set to withdraw FIFA boycott threat ahead of Champions League draw
-
Search for missing after Nepal-Tibet floods kill 165
-
Sumo moves to beat Japan summer heat as temperatures rise
-
Qantas says profits slump as fuel costs surge
-
'Be more honest': Markets crave clarity from cryptic Fed chair
-
Lofty bond yields, Bessent's intervention pose challenge to Fed's Warsh
-
Climate change leaves its mark on America's largest reservoir
-
The foreigners missing in Nepal's flash floods
-
CIA director warned Russia not to attack NATO members: US media
-
Bond yields are surging: Here's why that could spell trouble
-
Search for missing after Nepal-Tibet floods kills at least 160
-
Fed's Cook rejects Trump mortgage fraud claims
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
M.King--AT